RZLT icon

Rezolute

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 80%
Negative

Neutral
GlobeNewsWire
2 days ago
Rezolute to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced that management will participate in the following investor conferences: Event: Maxim Growth Summit Date: October 22-23, 2025 Event: Guggenheim 2nd Annual Healthcare Innovation Conference Date: November 10-12, 2025 Event: Jefferies London Healthcare Conference Date: November 17-20, 2025 Management will be participating in one-on-one investor meetings throughout the conferences.
Rezolute to Participate in Upcoming Investor Conferences
Neutral
GlobeNewsWire
7 days ago
Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ: RZLT), (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced that it has granted as of September 30, 2025 equity inducement awards to two new employees. The equity awards were approved by the Compensation Committee of the Company's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and were made as a material inducement to the employees' acceptance of employment with Rezolute.
Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Neutral
GlobeNewsWire
29 days ago
Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update
REDWOOD CITY, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today reported financial results and provided a business update for the fourth quarter and full fiscal year ended June 30, 2025.
Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update
Positive
MarketBeat
1 month ago
Rezolute Stock: FDA Fast Track Fuels 2025 Breakout
Rezolute, Inc.'s NASDAQ: RZLT stock price is steadily moving higher in 2025 and is expected to continue its run because of what adds up to a rapidly improving outlook. Its lead pharmaceutical candidate, Ersodetug, was granted the FDA's Breakthrough Therapy designation, which puts it on a fast track for approval.
Rezolute Stock: FDA Fast Track Fuels 2025 Breakout
Positive
Seeking Alpha
1 month ago
Rezolute: FDA Pivotal Trial Alignment Change Further Bolsters Ersodetug
Rezolute is advancing ersodetug in two phase 3 trials for hyperinsulinism: sunRIZE for congenital HI and upLIFT for tumor HI, respectively. RZLT secured FDA alignment for the upLIFT pivotal trial, allowing for an open-label design and only needing to recruit 16 patients. Topline data for sunRIZE is expected in December 2025, while upLIFT results are anticipated in the second half of 2026, offering key catalysts for investors to look forward to.
Rezolute: FDA Pivotal Trial Alignment Change Further Bolsters Ersodetug
Neutral
Seeking Alpha
1 month ago
Rezolute, Inc. (RZLT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Rezolute, Inc. (NASDAQ:RZLT ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 12:20 PM EDT Company Participants Nevan Elam - Founder, CEO, Principal Financial Officer & Acting Chairman of the Board Conference Call Participants Kelly McCarthy Presentation Kelly McCarthy All right. Good afternoon, everyone.
Rezolute, Inc. (RZLT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Neutral
GlobeNewsWire
1 month ago
Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism
Open-label study in as few as 16 tumor hyperinsulinism (HI) patients Study initiated and enrolling patients in the U.S. and Europe Topline data expected in the second half of 2026 REDWOOD CITY, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced that the Company has gained alignment with FDA on a significantly streamlined clinical development path for its ongoing Phase 3 study (upLIFT) of ersodetug for the treatment of hypoglycemia caused by tumor HI.
Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism
Neutral
GlobeNewsWire
1 month ago
Rezolute to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced that management will participate in the following investor conferences:
Rezolute to Participate in Upcoming Investor Conferences
Neutral
GlobeNewsWire
1 month ago
Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer
Experienced commercial and biopharmaceuticals leader to spearhead launch strategy and global market readiness for ersodetug Experienced commercial and biopharmaceuticals leader to spearhead launch strategy and global market readiness for ersodetug
Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer
Neutral
GlobeNewsWire
2 months ago
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
REDWOOD CITY, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced that management will participate in the BTIG Virtual Biotechnology Conference, taking place July 29-30, 2025.
Rezolute to Participate in the BTIG Virtual Biotechnology Conference